BACKGROUND: Irinotecan hydrochloride, a topoisomerase I inhibitor, has been preliminarily recognized as an effective agent against clear cell carcinoma of the ovary (CCC), but there are few clinical data. Our aim was to compare progression-free survival (PFS) between patients treated with irinotecan hydrochloride and cisplatin (CPT-P) and those with treated with paclitaxel and carboplatin (TC). METHODS: One hundred and seventeen patients at International Federation of Gynecology and Obstetrics (FIGO) stages Ic (ascites/malignant washing) - IV were identified by scanning the medical records of ten Japanese hospitals. After complete surgical staging procedures including lymphadenectomy, 35 patients received CPT-P and 82 patients received TC. The PFS and overall survival of the two groups were compared using the Kaplan-Meier method. RESULTS: There was no significant difference in median age, performance status, FIGO stage, rate of optimal cytoreduction, or follow-up period between the CPT-P and TC groups. Two-year and 5-year PFS was 48% and 40%, respectively, in the TC group and 55% and 55%, respectively, in the CPT-P group (P = 0.31). Multiple regression analysis revealed that only residual tumor was an independent prognostic factor for PFS (P < 0.01). CONCLUSION: CPT-P showed a potential therapeutic effect, at least no less than that of TC therapy. Although there was no significant survival benefit in the present retrospective analysis, we recommend that the CPT-P regimen be evaluated in a larger, prospective, clinical trial.
BACKGROUND:Irinotecan hydrochloride, a topoisomerase I inhibitor, has been preliminarily recognized as an effective agent against clear cell carcinoma of the ovary (CCC), but there are few clinical data. Our aim was to compare progression-free survival (PFS) between patients treated with irinotecan hydrochloride and cisplatin (CPT-P) and those with treated with paclitaxel and carboplatin (TC). METHODS: One hundred and seventeen patients at International Federation of Gynecology and Obstetrics (FIGO) stages Ic (ascites/malignant washing) - IV were identified by scanning the medical records of ten Japanese hospitals. After complete surgical staging procedures including lymphadenectomy, 35 patients received CPT-P and 82 patients received TC. The PFS and overall survival of the two groups were compared using the Kaplan-Meier method. RESULTS: There was no significant difference in median age, performance status, FIGO stage, rate of optimal cytoreduction, or follow-up period between the CPT-P and TC groups. Two-year and 5-year PFS was 48% and 40%, respectively, in the TC group and 55% and 55%, respectively, in the CPT-P group (P = 0.31). Multiple regression analysis revealed that only residual tumor was an independent prognostic factor for PFS (P < 0.01). CONCLUSION: CPT-P showed a potential therapeutic effect, at least no less than that of TC therapy. Although there was no significant survival benefit in the present retrospective analysis, we recommend that the CPT-P regimen be evaluated in a larger, prospective, clinical trial.
Authors: Hiroshi Tsuda; Yoichi M Ito; Yasuo Ohashi; Kwong-Kwok Wong; Yasunori Hashiguchi; William R Welch; Ross S Berkowitz; Michael J Birrer; Samuel C Mok Journal: Clin Cancer Res Date: 2005-10-01 Impact factor: 12.531
Authors: B A Goff; R Sainz de la Cuesta; H G Muntz; D Fleischhacker; M Ek; L W Rice; N Nikrui; H K Tamimi; J M Cain; B E Greer; A F Fuller Journal: Gynecol Oncol Date: 1996-03 Impact factor: 5.482
Authors: H Utsunomiya; J Akahira; S Tanno; T Moriya; M Toyoshima; H Niikura; K Ito; Y Morimura; Y Watanabe; N Yaegashi Journal: Int J Gynecol Cancer Date: 2006 Jan-Feb Impact factor: 3.437
Authors: M Takano; Y Kikuchi; N Yaegashi; K Kuzuya; M Ueki; H Tsuda; M Suzuki; J Kigawa; S Takeuchi; H Tsuda; T Moriya; T Sugiyama Journal: Br J Cancer Date: 2006-05-22 Impact factor: 7.640
Authors: Robert S Mannel; Mark F Brady; Elise C Kohn; Parviz Hanjani; Masamichi Hiura; Roger Lee; Koen Degeest; David E Cohn; Bradley J Monk; Helen Michael Journal: Gynecol Oncol Date: 2011-05-06 Impact factor: 5.482
Authors: Andrew Bryant; Shaun Hiu; Patience T Kunonga; Ketankumar Gajjar; Dawn Craig; Luke Vale; Brett A Winter-Roach; Ahmed Elattar; Raj Naik Journal: Cochrane Database Syst Rev Date: 2022-09-26